These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26707628)

  • 21. Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.
    Anzalone N; Castellano A; Cadioli M; Conte GM; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Grillea G; Vitali P; Aquino D; Terreni MR; Torri V; Erickson BJ; Caulo M
    Radiology; 2018 Jun; 287(3):933-943. PubMed ID: 29361245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading.
    Su CQ; Lu SS; Han QY; Zhou MD; Hong XN
    Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
    Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
    Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential diagnosis of central lymphoma and high-grade glioma: dynamic contrast-enhanced histogram.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Feng YN; Wang MZ
    Acta Radiol; 2020 Sep; 61(9):1221-1227. PubMed ID: 31902220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas.
    Jia L; Wu X; Wan Q; Wan L; Jia W; Zhang N
    Br J Radiol; 2021 Mar; 94(1119):20200699. PubMed ID: 33332981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
    Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
    Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
    Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
    Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance of texture analysis on MRI in grading cerebral gliomas.
    Skogen K; Schulz A; Dormagen JB; Ganeshan B; Helseth E; Server A
    Eur J Radiol; 2016 Apr; 85(4):824-9. PubMed ID: 26971430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The value of DCE-MRI in predicting IDH gene mutation of high-grade gliomas].
    Lu HT; Xing W; Zhang YW; Qin HP; Wu RH; Ding JL
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3105-3109. PubMed ID: 31648456
    [No Abstract]   [Full Text] [Related]  

  • 31. Histogram analysis of T2*-based pharmacokinetic imaging in cerebral glioma grading.
    Liu HS; Chiang SW; Chung HW; Tsai PH; Hsu FT; Cho NY; Wang CY; Chou MC; Chen CY
    Comput Methods Programs Biomed; 2018 Mar; 155():19-27. PubMed ID: 29512499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?
    White ML; Zhang Y; Kirby P; Ryken TC
    AJNR Am J Neuroradiol; 2005 Apr; 26(4):784-90. PubMed ID: 15814921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of oligodendrogliomas.
    Lebrun C; Fontaine D; Ramaioli A; Vandenbos F; Chanalet S; Lonjon M; Michiels JF; Bourg V; Paquis P; Chatel M; Frenay M;
    Neurology; 2004 May; 62(10):1783-7. PubMed ID: 15159478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar grades using conventional and T1-weighted DCE-MRI.
    Gupta M; Gupta A; Yadav V; Parvaze SP; Singh A; Saini J; Patir R; Vaishya S; Ahlawat S; Gupta RK
    Neuroradiology; 2021 Aug; 63(8):1227-1239. PubMed ID: 33469693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI based texture analysis to classify low grade gliomas into astrocytoma and 1p/19q codeleted oligodendroglioma.
    Zhang S; Chiang GC; Magge RS; Fine HA; Ramakrishna R; Chang EW; Pulisetty T; Wang Y; Zhu W; Kovanlikaya I
    Magn Reson Imaging; 2019 Apr; 57():254-258. PubMed ID: 30465868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
    Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
    Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes.
    Emblem KE; Scheie D; Due-Tonnessen P; Nedregaard B; Nome T; Hald JK; Beiske K; Meling TR; Bjornerud A
    AJNR Am J Neuroradiol; 2008 Oct; 29(9):1664-70. PubMed ID: 18583405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.
    Sunwoo L; Choi SH; Yoo RE; Kang KM; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Park SW; Sohn CH; Won JK; Park SH; Kim IH
    Neuroradiology; 2015 Nov; 57(11):1111-20. PubMed ID: 26232204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.
    Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Martinez-Zalacain I; Castell J; Camins A; Vidal N; Bruna J; Cos M; Perez-Lopez R; Oleaga L; Warnert E; Smits M; Majos C
    Eur Radiol; 2024 Aug; 34(8):5320-5330. PubMed ID: 38282078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of Hemangioblastoma from Metastatic Brain Tumor using Dynamic Contrast-enhanced MR Imaging.
    Cha J; Kim ST; Nam DH; Kong DS; Kim HJ; Kim YK; Kim HY; Park GM; Jeon P; Kim KH; Byun HS
    Clin Neuroradiol; 2017 Sep; 27(3):329-334. PubMed ID: 26952018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.